EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

Joanne Ellis iD, Léa Fortunato, Hannah Wajdner, Ester Del Duca, Joanna Barnard, Joanna C Betts iD, Swaroop Bose, John Browning, Núria Buil-Bruna, Scott Van Buren iD, Eden David iD, Scott Dinehart iD und 21 weitere

Allergy · 2026-02 · 81 (2) · 539-551

DOI: 10.1111/all.70172 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 18.12.2025. Verfasst von Joanne Ellis und 32 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Stevenage, UK. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Interleukin-18, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study (GSK Study 215253; NCT04975438) was funded by GSK. Medical writing support was provided by Eleri Ashworth, PhD, & Nicholas Thomas, PhD, at Fishawack…, GSK, GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin‐18 (IL‐18) is a pleiotropic cytokine implicated in atopic dermatitis (AD), affecting both type (T)1 and T2 immune pathways. An anti–IL‐18 monoclonal antibody, aletekitug, was evaluated for its clinical and molecular effects in patients with moderate to severe AD.

Methods

This randomised, double‐blind, parallel‐group, placebo‐controlled, 24‐week study assessed adults with moderate‐to‐severe AD who were biologic‐naïve or dupilumab‐inadequate responders/intolerant. Participants received a single intravenous (IV) infusion of aletekitug 2 mg/kg or placebo. The primary endpoint was percentage change from baseline (PCFB) in Eczema Area and Severity Index (EASI) score at Week 12. Other endpoints included safety, patient‐reported outcomes (PROs) and transcriptomics.

Results

Thirty‐four participants (aletekitug, n = 23; placebo, n = 11) were randomised. A greater reduction in the PCFB in EASI score at Week 12 was demonstrated for patients who received aletekitug versus placebo (posterior median PCFB [95% credible intervals]: aletekitug, −68.3% [−79.68, −56.68]; placebo, −32.9% [−45.74, −21.10]), with effects still apparent at Week 24. Aletekitug improved PRO measures of itch, sleep disturbance, fatigue and quality of life versus placebo up to Week 24. Transcriptome analysis suggested aletekitug modulated lesional skin towards a non‐lesional profile and exerted broad immunomodulatory effects, impacting several AD‐associated signalling pathways, not limited to T2 immunity. Aletekitug was well tolerated, with no serious adverse events reported.

Conclusion

A single 2 mg/kg IV dose of aletekitug was associated with improved outcomes at Week 12, which were sustained to Week 24, and modulated immune mechanisms beyond T2 inflammation. These results support IL‐18 as a potential therapeutic target in moderate‐to‐severe AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicInterleukin-18Antibodies, MonoclonalHumansAdultMaleFemaleMiddle AgedTreatment OutcomeDouble-Blind MethodSeverity of Illness Index

Stichwörter der Autor:innen

atopic dermatitisbiologicsbiomarkersdermatologyinterleukins

Substanzen

Interleukin-18Antibodies, Monoclonal

Autor:innen und Institutionen

  • GSK, Stevenage, UK.
  • GSK, Rueil-Malmaison, France.
  • Mount Sinai Medical Center, New York, USA.
  • University of Texas Health San Antonio, San Antonio, Texas, USA.
  • GSK, Collegeville, Pennsylvania, USA.
  • Arkansas Dermatology, Little Rock, Arkansas, USA.

ORCID-Profile: Joanne Ellis, Joanna C Betts, Scott Van Buren, Eden David, Scott Dinehart, Fiona Lovegrove, Jenny Lowe, Will Powley, Naveen Prasad, Chun-Hang Tang, John B Kelly, Emma Guttman-Yassky

Förderung

  • This study (GSK Study 215253; NCT04975438) was funded by GSK. Medical writing support was provided by Eleri Ashworth, PhD, & Nicholas Thomas, PhD, at Fishawack…
  • GSK
  • GlaxoSmithKline

Zitieren

APA

Ellis, J., Fortunato, L., Wajdner, H., Del Duca, E., Barnard, J., Betts, J. C., Bose, S., Browning, J., Buil-Bruna, N., Van Buren, S., David, E., Dinehart, S., Dhawan, P., Estrada, Y., Ghafoori, P., Gumireddy, K., Li, Z., Loo, W. J., Lovegrove, F., …, & Guttman-Yassky, E. (2026). Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis. Allergy, 81(2), 539-551. https://doi.org/10.1111/all.70172

Vancouver

Ellis J, Fortunato L, Wajdner H, Del Duca E, Barnard J, Betts JC, et al. Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis. Allergy. 2026;81(2):539-551. doi:10.1111/all.70172

BibTeX
@article{Ellis2026,
  author = {Ellis, Joanne and Fortunato, Léa and Wajdner, Hannah and Del Duca, Ester and Barnard, Joanna and Betts, Joanna C and Bose, Swaroop and Browning, John and Buil-Bruna, Núria and Van Buren, Scott and David, Eden and Dinehart, Scott and Dhawan, Puneet and Estrada, Yeriel and Ghafoori, Parima and Gumireddy, Kiranmai and Li, Zhenghong and Loo, Wei Jing and Lovegrove, Fiona and Lowe, Jenny and Parish, Lawrence Charles and Powley, Will and Prasad, Naveen and Da Rosa, Joel Correa and Ruseva, Marieta and Shokrian, Neda and Syed, Farhat and Tang, Chun-Hang and Wong, Gabriel K and Kelly, John B and Wisniacki, Nicolas and Uings, Iain and Guttman-Yassky, Emma},
  title = {Clinical and Molecular Effect of the Anti– IL ‐18 Antibody Aletekitug in Adults With Atopic Dermatitis},
  journal = {Allergy},
  year = {2026},
  volume = {81},
  number = {2},
  pages = {539--551},
  doi = {10.1111/all.70172}
}
Kostenlos starten →